UCB SA (OTCMKTS:UCBJY – Get Free Report) passed above its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of $83.94 and traded as high as $89.35. UCB shares last traded at $89.26, with a volume of 4,597 shares trading hands.
UCB Stock Up 0.3 %
The business has a fifty day simple moving average of $83.94 and a two-hundred day simple moving average of $71.98.
UCB Company Profile
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.
Read More
- Five stocks we like better than UCB
- Manufacturing Stocks Investing
- Goldilocks CPI Report Leads Market to Sell Off, Lower Lows Ahead
- What is an Earnings Surprise?
- GameStop: Earnings Won’t Save It, Dilution Points to Trouble
- Basic Materials Stocks Investing
- Dividend Aristocrats or Dividend Kings: Which Is Best for You?
Receive News & Ratings for UCB Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UCB and related companies with MarketBeat.com's FREE daily email newsletter.